GSK stops Phase 3 trial on cUTIs for efficacy | 28-May-2025 | 12:00 | RNS |
Transaction in Own Shares | 28-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 27-May-2025 | 07:00 | RNS |
positive CHMP opinion on Blenrep in EU | 23-May-2025 | 12:16 | RNS |
Transaction in Own Shares | 23-May-2025 | 07:00 | RNS |
FDA approves Nucala COPD indication | 23-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 22-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 21-May-2025 | 07:00 | RNS |
Director/PDMR Shareholding | 20-May-2025 | 15:30 | RNS |
Transaction in Own Shares | 20-May-2025 | 07:00 | RNS |
Blenrep for 2L+ multiple myeloma approved in Japan | 19-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 19-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 16-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 15-May-2025 | 07:00 | RNS |
GSK to acquire efimosfermin | 14-May-2025 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 1,446.50p |
Change Today | -1.50p |
% Change | -0.10 % |
52 Week High | 1,766.50 |
52 Week Low | 1,264.00 |
Volume | 6,233,729 |
Shares Issued | 4,099.70m |
Market Cap | £59,302m |
RiskGrade | 129 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 4 |
Buy | 2 |
Neutral | 14 |
Sell | 3 |
Strong Sell | 1 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q1 | Q4 | |
Ex-Div | 15-May-25 | 20-Feb-25 |
Paid | 10-Jul-25 | 10-Apr-25 |
Amount | 16.00p | 16.00p |
Time | Volume / Share Price |
15:25 | 1 @ 1,451.00p |
15:08 | 1 @ 1,453.00p |
15:08 | 1 @ 1,453.00p |
15:08 | 1 @ 1,453.00p |
15:18 | 2 @ 1,450.50p |
You are here: research